First RSV jab approved

The Therapeutic Goods Administration has approved a vaccine against respiratory syncytial virus, for Australians aged 60 and over AREXVY (respiratory syncytial virus vaccine, adjuvanted) is the first RSV vaccine to be approved for use in Australia. In welcoming the news, GSK Australia noted that while RSV is often considered as an illness mainly affecting children,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Priceline sole pharmacy brand in top 100
Next World news wrapup: 18 January 2024